重组人血管内皮抑制素治疗肺癌患者的临床疗效

Effect of Recombinant Human Endostatin on the Treatment of Lung Cancer

目的探讨重组人血管内皮抑制素治疗肺癌患者的临床治疗效果。方法选取2013年8月至2014年8月吉林省肿瘤医院收治的肺癌患者184例为研究对象,按随机数字表法分为观察组和对照组,每组92例。对照组患者给予常规西药治疗,观察组患者在对照组治疗的基础上给予重组人血管内皮抑制素治疗。比较两组患者的治疗效果。结果对照组患者的治疗总有效率为68.5%,观察组患者的治疗总有效率为89.1%,观察组患者的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组及对照组患者的不良反应发生率分别为4.3%、13.0%,观察组患者的不良反应发生率更低,差异有统计学意义(P<0.05)。结论采用重组人血管内皮抑制素治疗肺癌患者,可取得较好的治疗效果。

Objective To analyze and observe the effect of recombinant human endostatin in the treatment of patients with lung cancer.Methods Randomly selected from August 2014 to August 2013,184 patients with lung cancer,in accordance with the principle of random allocation of computers divided into two groups,each of 92 cases. The control group received conventional western medicine treatment,the study group were treated with recombinant human endostatin.To compare the therapeutic effect of the two groups of patients.Results The total effective rate was 68.5% in the control group,the total effective rate was 89.1% in the study group,higher in the study group（P0.05）, the adverse reaction rate was 4.3%,13.0% in the study group and the control group（P0.05）.Conclusion The application of recombinant human endostatin in the treatment of lung cancer patients with constipation can achieve good results.